Skip to Content
Merck
  • Synergistic effects between catalase inhibitors and modulators of nitric oxide metabolism on tumor cell apoptosis.

Synergistic effects between catalase inhibitors and modulators of nitric oxide metabolism on tumor cell apoptosis.

Anticancer research (2014-10-03)
Katrin Scheit, Georg Bauer
ABSTRACT

Inhibitors of catalase (such as ascorbate, methyldopa, salicylic acid and neutralizing antibodies) synergize with modulators of nitric oxide (NO) metabolism (such as arginine, arginase inhibitor, NO synthase-inducing interferons and NO dioxygenase inhibitors) in the singlet oxygen-mediated inactivation of tumor cell protective catalase. This is followed by reactive oxygen species (ROS)-dependent apoptosis induction. TGF-beta, NADPH oxidase-1, NO synthase, dual oxidase-1 and caspase-9 are characterized as essential catalysts in this process. The FAS receptor and caspase-8 are required for amplification of ROS signaling triggered by individual compounds, but are dispensable when the synergistic effect is established. Our findings explain the antitumor effects of catalase inhibitors and of compounds that target NO metabolism, as well as their synergy. These data may have an impact on epidemiological studies related to secondary plant compounds and open new perspectives for the establishment of novel antitumor drugs and for the improvement of established chemotherapeutics.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Nω-Nitro-L-arginine methyl ester hydrochloride, ≥97% (TLC), powder
Sigma-Aldrich
Salicylic acid, ReagentPlus®, ≥99%
Sigma-Aldrich
Salicylic acid, ≥99%, FG
Sigma-Aldrich
Salicylic acid, ACS reagent, ≥99.0%
Supelco
Salicylic acid, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Salicylic acid, United States Pharmacopeia (USP) Reference Standard